Lead Sponsor

AstraZeneca

Age

18 - 130 years

Sex

ALL

Healthy Volunteers

No

•Aged at least 18 years.
•Documented evidence of NSCLC (stage IIIB/IV disease)
•Disease progression or recurrence after both a platinum-based chemotherapy and at least 1 additional regimen for treatment of NSCLC
•World Health Organisation (WHO) Performance Status of 0 or 1
•Estimated life expectancy of more than 12 weeks
•Patient's tumour sample must be PD-L1 positive (≥25%of tumour cells with membrane staining (Cohort 1 and 2) or PD-L1 positive with ≥90% of tumour cells with membrane staining (Cohort 3))

•Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
•Brain metastases or spinal cord compression or unless asymptomatic, treated and stable (not requiring steroids).
•Active or prior autoimmune disease or history of immunodeficiency
•Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.
•Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.
•Any unresolved toxicity CTCAE \>Grade 2 from previous anti-cancer therapy.
•Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \>Grade 1
•Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)

Related studies

NCT06043817 · Non-Small Cell Lung Cancer, NSCLC, and more

NCT07144280 · Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, and more

NCT07431827 · Non-small Cell Lung Cancer

NCT06758401 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, and more

NCT06427941 · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, and more

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer